当前位置: 首页 > 期刊 > 《中国药房》 > 2025年第15期
编号:2440082
来特莫韦预防异基因造血干细胞移植后巨细胞病毒感染的有效性与安全性分析
http://www.100md.com 2025年9月2日 中国药房 2025年第15期
     中图分类号 R978.7;R551 文献标志码A 文章编号 1001-0408(2025)15-1904-06

    DOI 10.6039/j.issn.1001-0408.2025.15.15

    Efficacyand safety of letermovir in preventing cytomegalovirus infection after allogeneic hematopoietic ;tem cell transplantation

    WANG Ranran1.2,LI Shuyuel,3,LIANG Ranran1,4,SONG Xianmin5,TANG Yuanjun1,GAO Junwei1(1. Dept.of Clinical Pharmacy,Shanghai General Hospital Afiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 2Oo08O,China;2.Dept.of Clinical Pharmacy,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200092,China;3.Dept.of Pharmacy,Shanxi Cancer Hospital/Shanxi Hospital of Chinese Academy of Medical Sciences Cancer Hospital,Taiyuan O30013,China;4.Dept.of Pharmacy,the Second Afiliated Hospital of Shandong First Medical University,Shandong Taian 271000, China;5.Dept.of Hematology,Shanghai General Hospital Afiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 20oo80,China)

    ABSTRACTOBJECTIVETo evaluate theeficacyand safetyof letermovir in preventing cytomegalovirus(CMV)infection fterallgeneichematopoieticstemcelltransplantation(all-HSCT).METHODSAretrospectivecohort studywasconducted ......

您现在查看是摘要页,全文长 21914 字符